• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自BALB/c - 3T3细胞的一种生长特异性cDNA的推定蛋白与小鼠白细胞介素1受体的胞外部分高度相似。

A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor.

作者信息

Tominaga S

机构信息

Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

出版信息

FEBS Lett. 1989 Dec 4;258(2):301-4. doi: 10.1016/0014-5793(89)81679-5.

DOI:10.1016/0014-5793(89)81679-5
PMID:2532153
Abstract

A cDNA clone, which represents a species of mRNA that is expressed in growth-stimulated BALB/c-3T3 cells but not in resting cells, was found to encode a protein remarkably similar in sequence to the members of the immunoglobulin superfamily, especially to the extracellular portion of the mouse interleukin 1 receptor. The immunoglobulin superfamily is believed to be involved in cell adhesion and cell-to-cell interaction. The evidence that a member of this family is induced in the course of the initiation of cell proliferation is intriguing.

摘要

发现一个cDNA克隆,它代表一种在生长刺激的BALB/c - 3T3细胞中表达而在静止细胞中不表达的mRNA物种,该克隆编码的蛋白质在序列上与免疫球蛋白超家族成员非常相似,尤其与小鼠白细胞介素1受体的细胞外部分相似。免疫球蛋白超家族被认为参与细胞黏附和细胞间相互作用。该家族的一个成员在细胞增殖起始过程中被诱导,这一证据很有趣。

相似文献

1
A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor.来自BALB/c - 3T3细胞的一种生长特异性cDNA的推定蛋白与小鼠白细胞介素1受体的胞外部分高度相似。
FEBS Lett. 1989 Dec 4;258(2):301-4. doi: 10.1016/0014-5793(89)81679-5.
2
cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily.白细胞介素-1受体的cDNA表达克隆,免疫球蛋白超家族成员之一。
Science. 1988 Jul 29;241(4865):585-9. doi: 10.1126/science.2969618.
3
Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity.NKp46的分子克隆:免疫球蛋白超家族中参与触发自然细胞毒性的一个新成员。
J Exp Med. 1998 Sep 7;188(5):953-60. doi: 10.1084/jem.188.5.953.
4
Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping.小鼠ST2基因的分子克隆。特性分析与染色体定位。
Biochim Biophys Acta. 1991 Aug 27;1090(1):1-8. doi: 10.1016/0167-4781(91)90029-l.
5
Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily.编码人和小鼠B淋巴细胞CD19抗原的cDNA的分离。免疫球蛋白超家族的一个新成员。
J Immunol. 1989 Jul 15;143(2):712-7.
6
Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49.
J Biol Chem. 1994 Mar 18;269(11):8393-401.
7
Molecular cloning, characterization and functional expression of the rat liver interleukin 6 receptor.大鼠肝脏白细胞介素6受体的分子克隆、特性鉴定及功能表达
J Biol Chem. 1990 Nov 15;265(32):19853-62.
8
Molecular cloning and expression of the human interleukin 5 receptor.人白细胞介素5受体的分子克隆与表达
J Exp Med. 1992 Feb 1;175(2):341-51. doi: 10.1084/jem.175.2.341.
9
A new member of the immunoglobulin superfamily--CTLA-4.免疫球蛋白超家族的一个新成员——细胞毒性T淋巴细胞相关抗原4。
Nature. 1987;328(6127):267-70. doi: 10.1038/328267a0.
10
Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily.人及小鼠白细胞介素-7受体的克隆:可溶性形式的证明及其与新受体超家族的同源性
Cell. 1990 Mar 23;60(6):941-51. doi: 10.1016/0092-8674(90)90342-c.

引用本文的文献

1
Dynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study.射血分数降低的心力衰竭(HFrEF)患者接受心力衰竭治疗时新型心脏生物标志物sST2、H-FABP、GDF-15和可溶性尿激酶型纤溶酶原激活物受体(suPAR)的动态变化:一项初步研究
J Clin Med. 2025 Aug 11;14(16):5668. doi: 10.3390/jcm14165668.
2
Interleukin-33 and Obesity-Related Inflammation and Cancer.白细胞介素-33与肥胖相关炎症及癌症
Encyclopedia (Basel, 2021). 2024 Dec;4(4):1770-1789. doi: 10.3390/encyclopedia4040117. Epub 2024 Nov 23.
3
IL-33/ST2 signalling promotes tumor growth by regulating polarization of alternatively activated macrophages.
白细胞介素-33/ST2信号通路通过调节交替激活巨噬细胞的极化促进肿瘤生长。
Cancer Biol Med. 2025 Mar 27;22(4):376-95. doi: 10.20892/j.issn.2095-3941.2024.0483.
4
Short-term predictive value of sST2 in patients with STEMI following primary PCI: a prospective observational study.sST2对ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后的短期预测价值:一项前瞻性观察研究。
BMC Cardiovasc Disord. 2025 Jan 15;25(1):21. doi: 10.1186/s12872-025-04488-z.
5
Studies of Structure-Activity Relationship of 2-(Pyrrolidin-1ylmethyl)-1-pyrrole-Based ST2 Inhibitors and Their Inhibition of Mast Cells Activation.基于2-(吡咯烷-1-基甲基)-1-吡咯的ST2抑制剂的构效关系及其对肥大细胞活化的抑制作用研究
ACS Med Chem Lett. 2024 Oct 18;15(11):2053-2059. doi: 10.1021/acsmedchemlett.4c00459. eCollection 2024 Nov 14.
6
Examining the Long-Term Prognostic Significance of Serum sST2: Influence of Myocardial Infarction History and Subgroup Level Standardization.探讨血清可溶性ST2的长期预后意义:心肌梗死病史及亚组水平标准化的影响
J Inflamm Res. 2024 Oct 25;17:7733-7744. doi: 10.2147/JIR.S482475. eCollection 2024.
7
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease.在健康志愿者和慢性阻塞性肺疾病患者中,托佐拉单抗的群体药代动力学/药效学建模。
Br J Clin Pharmacol. 2024 Dec;90(12):3286-3295. doi: 10.1111/bcp.16195. Epub 2024 Aug 25.
8
Soluble ST2: A Novel Biomarker for Diagnosis and Prognosis of Cardiovascular Disease.可溶性 ST2:心血管疾病诊断和预后的新型生物标志物。
Curr Med Sci. 2024 Aug;44(4):669-679. doi: 10.1007/s11596-024-2907-x. Epub 2024 Aug 3.
9
Correlations of sST2 and Gal-3 with Cardiothoracic Ratio in Patients with Chronic Kidney Disease.慢性肾脏病患者中可溶性生长刺激表达基因2蛋白(sST2)和半乳糖凝集素-3(Gal-3)与心胸比率的相关性
Biomedicines. 2024 Apr 3;12(4):791. doi: 10.3390/biomedicines12040791.
10
A type 1 immunity-restricted promoter of the IL-33 receptor gene directs antiviral T-cell responses.一种 1 型免疫受限的 IL-33 受体基因启动子指导抗病毒 T 细胞反应。
Nat Immunol. 2024 Feb;25(2):256-267. doi: 10.1038/s41590-023-01697-6. Epub 2024 Jan 3.